Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint

SUPERNUS PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$0.61 revenue$507,380,000

Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).
Qelbree net sales $81.4M (+31% YoY); GOCOVRI $40.8M (+15% YoY).
ONAPGO net sales $6.8M in first full quarter; supply constraint pauses new patient starts.
ZURZUVAE collab revenue $20.2M (post Sage acquisition); Q3 U.S. sales up ~150% YoY.
Full-year 2025 revenue guidance raised; cash $281.2M at Sep 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.